Younis T - Search Results

1

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Among authors: younis t. Breast. 2007 Jun;16(3):252-61. doi: 10.1016/j.breast.2006.12.002. Epub 2007 Jan 4. Breast. 2007. PMID: 17207623

2

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Among authors: younis t. Breast Cancer Res Treat. 2007 Mar;101(3):325-33. doi: 10.1007/s10549-006-9299-4. Epub 2006 Aug 2. Breast Cancer Res Treat. 2007. PMID: 16897433

3

Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.

Younis T, Rayson D, Dewar R, Skedgel C. Younis T, et al. Ann Oncol. 2007 Feb;18(2):293-8. doi: 10.1093/annonc/mdl410. Epub 2006 Nov 9. Ann Oncol. 2007. PMID: 17095569 Free article.

4

Wait times for breast cancer care.

Saint-Jacques N, Younis T, Dewar R, Rayson D. Saint-Jacques N, et al. Among authors: younis t. Br J Cancer. 2007 Jan 15;96(1):162-8. doi: 10.1038/sj.bjc.6603523. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179986 Free PMC article.

5

Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04.

Rayson D, Saint-Jacques N, Younis T, Meadows J, Dewar R. Rayson D, et al. Among authors: younis t. CMAJ. 2007 Jan 30;176(3):327-32. doi: 10.1503/cmaj.060825. CMAJ. 2007. PMID: 17261829 Free PMC article.

6

Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.

Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D. Dakin Haché K, et al. Among authors: younis t. Breast Cancer Res Treat. 2007 Oct;105(2):169-75. doi: 10.1007/s10549-006-9448-9. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268818

7

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.

Younis T, Rayson D, Sellon M, Skedgel C. Younis T, et al. Breast Cancer Res Treat. 2008 Sep;111(2):261-7. doi: 10.1007/s10549-007-9770-x. Epub 2007 Oct 5. Breast Cancer Res Treat. 2008. PMID: 17914669

8

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.

Au HJ, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, Jacobs P. Au HJ, et al. Among authors: younis t. Breast Cancer Res Treat. 2009 Apr;114(3):579-87. doi: 10.1007/s10549-008-0034-1. Epub 2008 Apr 29. Breast Cancer Res Treat. 2009. PMID: 18443903

9

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada.

Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. Drucker A, et al. Among authors: younis t. Curr Oncol. 2008 Jun;15(3):136-42. doi: 10.3747/co.v15i3.249. Curr Oncol. 2008. PMID: 18596891 Free PMC article.

10

Waiting times in early-stage non-small cell lung cancer (NSCLC).

Saint-Jacques N, Rayson D, Al-Fayea T, Virik K, Morzycki W, Younis T. Saint-Jacques N, et al. Among authors: younis t. J Thorac Oncol. 2008 Aug;3(8):865-70. doi: 10.1097/JTO.0b013e318180210c. J Thorac Oncol. 2008. PMID: 18670304 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

122 results

Search Page

Filters